PDE4 inhibitor (apremilast) in pemphigoid

Short-term safety, efficacy and mode of action of apremilast in mild to moderate cutaneous pemphigoid A phase IIa open label single arm study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21799

Enrollment

Registered

2018-07-16

Start date

2019-07-10

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigoid Pemfigioid

Interventions

Apremilast combined with doxycycline

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients with recently diagnosed mild to moderate localized or generalized cutaneous pemphigoid, or patients that were in complete remission without treatment that have a mild-moderate flare-up of the disease.

Exclusion criteria

Exclusion criteria: Contradiction or known allergy for PDE4 inhibitors. Women of childbearing potential without contraception, women who are pregnant or planning to become pregnant or who are lactating. Patients that use systemic immunosuppressive medication Any condition which would make the patient unsuitable for treatment, or requires steroid use.

Design outcomes

Primary

Measure	Time frame
Partial remission	—

Secondary

Measure	Time frame
Drug survival Complete remission	—

Contacts

Public ContactHanan Rashid

UMCG

h.rashid@umcg.nl050 3610701

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)